DDInter1570 DDInter927
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Ranolazine {u} (Compound) resembles {v} (Compound) Guaifenesin
Ranolazine {u} (Compound) resembles {v} (Compound) Bupivacaine
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
Ranolazine {u} (Compound) upregulates {v} (Gene) DENND2D
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Ranolazine {u} (Compound) downregulates {v} (Gene) ATP6V1D
Ranolazine {u} (Compound) causes {v} (Side Effect) Underweight
Ranolazine (Compound) resembles Guaifenesin (Compound)
Ranolazine (Compound) resembles Bupivacaine (Compound)
Ranolazine (Compound) binds CYP2D6 (Gene)
Ranolazine (Compound) upregulates DENND2D (Gene)
Ranolazine (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Ranolazine (Compound) downregulates ATP6V1D (Gene)
Ranolazine (Compound) causes Underweight (Side Effect)